Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Pipeline Review, H1 2018

  • ID: 4521343
  • Report
  • 130 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • AstraZeneca Plc
  • BeiGene Ltd
  • Clovis Oncology Inc
  • Tesaro Inc
  • MORE
Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Pipeline Review, H1 2018

Summary:

Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Poly [ADP-ribose] polymerase 2 is an enzyme encoded by the PARP2 gene.

It is involved in the base excision repair (BER) pathway, by catalyzing the poly (ADP-ribosylation) of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. This modification follows DNA damages and appears as an obligatory step in signaling pathway leading to the reparation of DNA strand breaks.

Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) pipeline Target constitutes close to 19 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes.

The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Discovery stages are 2, 3, 4, 7 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Ovarian Cancer, Breast Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Metastatic Breast Cancer, Small-Cell Lung Cancer, Solid Tumor, Gastric Cancer, Epithelial Ovarian Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Glioblastoma Multiforme (GBM), Metastatic Pancreatic Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Bile Duct Cancer (Cholangiocarcinoma), Cervical Cancer, Malignant Mesothelioma, Mantle Cell Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Transitional (Urothelial) Tract Cancer, Non-Hodgkin Lymphoma, Pancreatic Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), B-Cell Chronic Lymphocytic Leukemia, Bladder Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colorectal Cancer, Essential Thrombocythemia, Ewing Sarcoma, Follicular Lymphoma, Germ Cell Tumors, Germinomatous (Seminomatous) Germ Cell Tumors, Glioma, Gynecological Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Laryngeal Cancer, Leiomyosarcoma, Lung Cancer, Marginal Zone B-cell Lymphoma, Melanoma, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Prostate Cancer, Muscle Invasive Bladder Cancer (MIBC), Myelofibrosis, Neuroblastoma, Neuroendocrine Tumors, Nongerminomatous (Nonseminomatous) Germ Cell Tumors, Oropharyngeal Cancer, Pancreatic Ductal Adenocarcinoma, Peritoneal Tumor, Polycythemia Vera, Prostate Cancer, Rectal Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Soft Tissue Sarcoma, Squamous Non-Small Cell Lung Cancer, Testicular Cancer, Transitional Cell Cancer (Urothelial Cell Cancer) and Uveal Melanoma.

The latest report Poly [ADP Ribose] Polymerase 2 - Pipeline Review, H1 2018, outlays comprehensive information on the Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30)
  • The report reviews Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • AstraZeneca Plc
  • BeiGene Ltd
  • Clovis Oncology Inc
  • Tesaro Inc
  • MORE
Introduction

Report Coverage

Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Overview

Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Companies Involved in Therapeutics Development

AbbVie Inc

AstraZeneca Plc

BeiGene Ltd

Checkpoint Therapeutics Inc

Clovis Oncology Inc

Ildong Pharmaceutical Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Shanghai Acebright Pharmaceuticals Group Co Ltd

Tesaro Inc

Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Drug Profiles

2X-121 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABT-767 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZ-0108 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-1775 + olaparib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-6738 + olaparib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cediranib maleate + olaparib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CK-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IDX-1197 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

niraparib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

olaparib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pamiparib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rucaparib camsylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SC-10914 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHR-3162 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target PARP1, 2, 3 and NO for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SOMCL-9112 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tislelizumab + pamiparib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veliparib ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YHP-743 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Dormant Products

Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Discontinued Products

Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Product Development Milestones

Featured News & Press Releases

Apr 16, 2018: BeiGene Presents Clinical Data on Pamiparib in Chinese Patients with Ovarian Cancers or Triple-Negative Breast Cancer at the American Association for Cancer Research Annual Meeting

Apr 15, 2018: Updated Overall Survival Data for LYNPARZA (olaparib) in gBRCA-mutated HER2-Negative Metastatic Breast Cancer Presented at AACR

Apr 06, 2018: Rubraca (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer

Apr 03, 2018: The European Medicines Agency Accepts Regulatory Submission for Lynparza in BRCA-mutated HER2-Negative Metastatic Breast Cancer

Apr 02, 2018: Myriad Receives Pre-Market Approval for its BRACAnalysis Diagnostic System in Japan

Mar 26, 2018: Data From TOPACIO Trial Reported at SGO Demonstrates Compelling Clinical Activity of ZEJULA in Combination With an Anti-PD-1 Antibody in Patients With Platinum Resistant/Refractory Ovarian Cancer

Mar 26, 2018: EMA Recommends Granting a Conditional Marketing Authorisation for Rucaparib

Mar 14, 2018: TESARO to Present Data on ZEJULA at AACR 2018 Annual Meeting

Mar 08, 2018: Clovis Oncology Announces Notice of Allowance for Rucaparib High Dosage Strength Tablet Patent with Expiration in 2

Feb 27, 2018: TESARO Announces Fourth-Quarter and Full-Year 2017 Operating Results

Feb 23, 2018: Lynparza receives positive EU CHMP opinion in platinum-sensitive relapsed ovarian cancer

Feb 21, 2018: Clovis Oncology Receives Positive Trend Vote from CHMP in European Regulatory Review for Rucaparib Ovarian Cancer Treatment Indication

Feb 08, 2018: Once a day pill for ovarian cancer could be made available on the CDF

Feb 05, 2018: Newcastle University Provides Update on Anti-Neoplastic Agent Rucaparib

Jan 19, 2018: Lynparza receives approval in Japan for the treatment of advanced ovarian cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Products under Development by Companies, H1 2018 (Contd..7), H1 2018

Products under Development by Companies, H1 2018 (Contd..8), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by AbbVie Inc, H1 2018

Pipeline by AstraZeneca Plc, H1 2018

Pipeline by BeiGene Ltd, H1 2018

Pipeline by Checkpoint Therapeutics Inc, H1 2018

Pipeline by Clovis Oncology Inc, H1 2018

Pipeline by Ildong Pharmaceutical Co Ltd, H1 2018

Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018

Pipeline by Shanghai Acebright Pharmaceuticals Group Co Ltd, H1 2018

Pipeline by Tesaro Inc, H1 2018

Dormant Projects, H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • AstraZeneca Plc
  • BeiGene Ltd
  • Checkpoint Therapeutics Inc
  • Clovis Oncology Inc
  • Ildong Pharmaceutical Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Shanghai Acebright Pharmaceuticals Group Co Ltd
  • Tesaro Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll